GlassScriptPhysician profile
Beth Ann Cohen
NPI 1619017662
$2,645.26
in general payments reported to CMS, 2019-2025
30 companies · $715 in 2025
The $715 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $176 · 2021: $121 · 2022: $372 · 2023: $343 · 2024: $338 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $539.51 | 2019-2025 | Bexsero, Pediarix, Nucala |
| Emergent Biosolutions INC. | $339.78 | 2019 | |
| Kaleo, INC. | $327.62 | 2019-2024 | Auvi-Q |
| Kyowa Kirin, INC. | $243.48 | 2025 | |
| Novo Nordisk INC | $135.09 | 2019-2025 | Sogroya |
| Pfizer INC. | $124.79 | 2019-2025 | |
| Genentech USA, INC. | $112.91 | 2019-2024 | Xolair |
| Merck Sharp & Dohme LLC | $107.87 | 2020-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Ascendis Pharma Endocrinology INC | $104.82 | 2023-2025 | Skytrofa |
| Novartis Pharmaceuticals Corporation | $63.52 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $47.50 | 2025 | Triptodur |
| Seqirus USA INC | $47.24 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Endo USA, INC. | $46.61 | 2025 | Supprelin |
| Tolmar Pharmaceuticals, INC. | $39.53 | 2022 | |
| Neurocrine Biosciences, INC. | $37.15 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $28.68 | 2025 | Omnitrope |
| Tolmar, INC. | $27.44 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.66 | 2024 | Cuvitru |
| Sobi, INC | $24.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.21 | 2023 | Flumist Quadrivalent |
| Ibsa Pharma INC. | $24.15 | 2023 | Tirosint, Licart |
| Hologic Sales and Service, LLC | $23.51 | 2025 | Aptima |
| Sanofi-Aventis U.S. LLC | $22.98 | 2025 | |
| Endo Pharmaceuticals INC. | $22.87 | 2019 | |
| Phadia US INC. | $19.87 | 2025 | Immunocap |
| Alexion Pharmaceuticals, INC. | $19.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.61 | 2020 | |
| Avion Pharmaceuticals | $15.78 | 2019 | |
| Cranial Technologies, INC | $15.52 | 2023 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.